Imunon Inc
IMNNBuild a strategy around IMNN
Imunon Inc AI Insights
Informational only. Not investment advice.Snapshot
- Zero revenue TTM with -14.5M operating loss - pure clinical-stage burn. Cash runway of 5.3M covers ~4 months at current -14.7M annual cash burn rate.[Cash and Equivalents / Cash Flow TTM]
- R&D of 7.5M TTM is 52% of total opex (14.5M) - lean structure but sub-scale vs industry median 37.6M R&D spend.[Research and Development TTM]
- Market cap 12.3M at 3.0x book value despite no revenue and negative equity returns (-233% ROE TTM).[P/B Ratio]
Watch Triggers
- Cash and Equivalents: Falls below 3M or financing announced — Sub-3M cash triggers going concern risk; financing terms dictate dilution severity
- Issuance of Capital Stock: New equity raise >5M or convertible debt — With 2.9M shares out, even 5M raise at current price doubles share count
- Research and Development TTM: Drops below 5M or spikes above 10M — R&D cut signals program abandonment; spike suggests pivotal trial advancement
Bull Case
Minimal debt (1.1M, 0.27 D/E) preserves financing flexibility. Clean balance sheet enables equity or partnership deals without creditor constraints.
Micro-cap (12.3M) with 2.9M shares outstanding - any positive clinical catalyst creates asymmetric upside on thin float.
Bear Case
Critical cash crisis: 5.3M cash funds only ~4 months of operations. Dilution or failure is near-certain without financing.
Zero revenue biotech trading at 3x book with -233% ROE - valuation assumes success not reflected in fundamentals.
Bull vs Bear Balance
AI-generated sentiment analysis based on fundamental metrics and market conditions.
Leverage IMNN's top insights and create a custom strategy based on them in seconds. Our AI editor does it all — in one click.
Forward Thesis
Imminent dilution required - 5.3M cash vs 14.7M annual burn forces capital raise within 6 months.
- Cash runway under 5 months at TTM burn rate
- 3.5M equity issuance TTM shows ongoing dilution pattern
- No revenue to offset operating losses
Valuation Context
Caveats
Public Strategies Rankings
See how Imunon Inc ranks across different investment strategies.
Leverage IMNN's top insights and create a custom strategy in seconds. Our AI editor does it all — in one click.
IMNN Fundamentals
| Metric | Value | YoY Growth | Industry Percentile |
|---|---|---|---|
$8.74M | — | ||
$4.59M | — | ||
0.00 | — | ||
$0 | — | ||
$-12.53 | — | ||
0% | 0.0% | — | |
0% | 0.0% | — | |
$-14.95M | — | ||
-234% | -85.4% | — | |
Beta 5Y (Monthly) | unknown | — |
IMNN Dividend History
IMNN Stock Splits
IMNN SEC Filings
| Filing Date | Report Date | Report Type | Filing Link |
|---|---|---|---|
11/13/25 | 09/30/25 | 10-Q | |
08/05/25 | 06/30/25 | 10-Q | |
05/12/25 | 03/31/25 | 10-Q | |
02/27/25 | 12/31/24 | Unknown | |
11/07/24 | 09/30/24 | 10-Q | |
08/14/24 | 06/30/24 | 10-Q | |
05/13/24 | 03/31/24 | 10-Q | |
03/28/24 | 12/31/23 | 10-K | |
11/14/23 | 09/30/23 | 10-Q | |
08/10/23 | 06/30/23 | 10-Q | |
05/11/23 | 03/31/23 | 10-Q | |
03/30/23 | 12/31/22 | 10-K | |
11/14/22 | 09/30/22 | 10-Q | |
08/15/22 | 06/30/22 | 10-Q | |
05/16/22 | 03/31/22 | 10-Q | |
03/31/22 | 12/31/21 | 10-K | |
11/15/21 | 09/30/21 | 10-Q | |
08/12/21 | 06/30/21 | 10-Q | |
05/14/21 | 03/31/21 | 10-Q | |
03/19/21 | 12/31/20 | 10-K | |
11/16/20 | 09/30/20 | 10-Q | |
08/14/20 | 06/30/20 | 10-Q | |
05/15/20 | 03/31/20 | 10-Q | |
03/25/20 | 12/31/19 | 10-K | |
11/14/19 | 09/30/19 | 10-Q | |
08/14/19 | 06/30/19 | 10-Q | |
05/15/19 | 03/31/19 | 10-Q | |
03/29/19 | 12/31/18 | 10-K | |
11/14/18 | 09/30/18 | 10-Q | |
08/14/18 | 06/30/18 | 10-Q | |
05/11/18 | 03/31/18 | 10-Q | |
03/27/18 | 12/31/17 | 10-K | |
11/14/17 | 09/30/17 | 10-Q | |
08/14/17 | 06/30/17 | 10-Q | |
05/12/17 | 03/31/17 | 10-Q | |
03/24/17 | 12/31/16 | 10-K | |
11/10/16 | 09/30/16 | 10-Q | |
08/15/16 | 06/30/16 | 10-Q | |
05/16/16 | 03/31/16 | 10-Q | |
03/30/16 | 12/31/15 | 10-K | |
11/05/15 | 09/30/15 | 10-Q | |
08/10/15 | 06/30/15 | 10-Q | |
05/11/15 | 03/31/15 | 10-Q | |
03/12/15 | 12/31/14 | 10-K | |
11/10/14 | 09/30/14 | 10-Q | |
08/07/14 | 06/30/14 | 10-Q | |
05/08/14 | 03/31/14 | 10-Q | |
03/13/14 | 12/31/13 | 10-K | |
11/12/13 | 09/30/13 | 10-Q | |
08/08/13 | 06/30/13 | 10-Q | |
05/09/13 | 03/31/13 | 10-Q | |
03/18/13 | 12/31/12 | 10-K | |
11/09/12 | 09/30/12 | 10-Q | |
08/14/12 | 06/30/12 | 10-Q | |
05/15/12 | 03/31/12 | 10-Q | |
03/15/12 | 12/31/11 | 10-K | |
11/10/11 | 09/30/11 | 10-Q | |
08/09/11 | 06/30/11 | 10-Q | |
05/12/11 | 03/31/11 | 10-Q | |
03/28/11 | 12/31/10 | 10-K | |
11/15/10 | 09/30/10 | 10-Q | |
08/03/10 | 06/30/10 | 10-Q | |
05/04/10 | 03/31/10 | 10-Q | |
03/17/10 | 12/31/09 | 10-K | |
11/10/09 | 09/30/09 | 10-Q | |
08/05/09 | 06/30/09 | 10-Q | |
05/12/09 | 03/31/09 | 10-Q | |
03/27/09 | 12/31/08 | 10-K | |
11/14/08 | 09/30/08 | 10-Q | |
08/14/08 | 06/30/08 | 10-Q | |
05/09/08 | 03/30/08 | Unknown | -- |
03/28/08 | 12/31/07 | 10-K | |
11/14/07 | 09/30/07 | 10-Q | |
08/09/07 | 06/30/07 | 10-Q | |
05/10/07 | 03/30/07 | Unknown | -- |
03/27/07 | 12/31/06 | 10-K | |
11/08/06 | 09/30/06 | 10-Q | |
08/09/06 | 06/30/06 | 10-Q | |
05/11/06 | 03/30/06 | Unknown | -- |
03/20/06 | 12/31/05 | 10-K | |
11/08/05 | 09/30/05 | 10-Q | |
08/09/05 | 06/30/05 | 10-Q | |
05/10/05 | 03/30/05 | Unknown | -- |
03/16/05 | 12/31/04 | 10-K | |
11/15/04 | 09/30/04 | 10-Q | |
08/06/04 | 06/30/04 | 10-Q | |
05/17/04 | 03/30/04 | Unknown | -- |
02/17/04 | 12/31/03 | 10-Q | |
12/29/03 | 09/30/03 | 10-K | |
08/14/03 | 06/30/03 | 10-Q | |
05/15/03 | 03/30/03 | Unknown | -- |
02/14/03 | 12/31/02 | 10-Q | |
12/30/02 | 09/30/02 | PRE 14A | |
08/13/02 | 06/30/02 | 10-Q | |
05/14/02 | 03/30/02 | Unknown | -- |
02/14/02 | 12/31/01 | 10-Q | |
12/28/01 | 09/30/01 | 10-K | |
08/14/01 | 06/30/01 | 10-Q | |
05/14/01 | 03/30/01 | Unknown | -- |
02/07/01 | 12/31/00 | 10-Q | |
12/28/00 | 09/30/00 | 10-K | |
08/14/00 | 06/30/00 | 10-Q | |
05/05/00 | 03/30/00 | Unknown | -- |